Wells Fargo cuts target for Bristol Myers Squibb stock to USD 60.00

Published on 10/14/2026 at 15:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 29, 2026. Bristol Myers Squibb stock costs EUR 51.27 on October 14, 2026, with USD 115.8 billion market value.

Analyst target and reporting date

Wells Fargo lowered its Bristol Myers Squibb price target to USD 60.00 on October 13, 2026.
Bristol Myers Squibb will report third-quarter 2026 results on October 29, 2026.
Bristol Myers Squibb stock costs EUR 51.27 at Lang & Schwarz on October 14, 2026 at 3:13 p.m. CEST.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Wells Fargo lowered its Bristol Myers Squibb price target from USD 65.00 to USD 60.00 while maintaining an Equal Weight rating, according to Investing.com on October 13, 2026. Bristol Myers Squibb was trading at EUR 51.27 at Lang & Schwarz on October 14, 2026 at 3:13 p.m. CEST.

Wells Fargo highlights Eliquis risk

The Wells Fargo target change puts attention on the companys product transition. The report cited upcoming loss-of-exclusivity events and growth-product execution as concerns, while management reaffirmed current guidance for Eliquis, according to Investing.com on October 13, 2026. The report also said Breyanzi growth remained strong and that a USD 200.0 million Opdivo inventory build from the second quarter could partly or fully reverse in the third quarter.

Results date brings a second marker

Bristol Myers Squibb is scheduled to report third-quarter 2026 results on October 29, 2026, with its conference call starting at 8:00 a.m. ET, according to the companys press release dated September 18, 2026. The date gives the market a defined checkpoint for the Eliquis transition and the growth portfolio.

Price and valuation frame

The current euro quote sits alongside a USD 115.8 billion market capitalization, a trailing price-to-earnings ratio of 12.48 and a 52-week USD range of 42.52 to 68.64, based on October 13, 2026 market data. Bristol Myers Squibbs 2025 full-year investor figures list USD 48.2 billion in revenue, USD 14.2 billion in operating cash flow and USD 5.0 billion returned to shareholders, according to its investor page.

Comparison with peers

Bristol Myers Squibb: price-to-earnings ratio 12.48, market capitalization USD 115.8 billion.

Eli Lilly and Company (USD): minus 1.36 percent, price-to-earnings ratio 39.14, market capitalization USD 1.1 trillion.

Merck & Co. (USD): minus 2.39 percent, price-to-earnings ratio 113.58, market capitalization USD 350.7 billion.

Trading remains the live measure

For investors, the Wells Fargo target of USD 60.00 and the October 29 reporting date provide two separate reference points, while the euro quote reflects the latest trading indication in Germany. The companys investor page identifies the primary listing as NYSE under ticker BMY.

The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.